Triple-Positive

Overview of triple-positive breast cancer, including what it is and where relevant support threads and overlapping subtype resources currently live

This section is for triple-positive breast cancer topics.

Triple-positive breast cancer means the cancer is:

• ER-positive

• PR-positive

• HER2-positive

That combination means it sits at the overlap of two major treatment logics:

• endocrine / receptor-positive treatment questions

• HER2-targeted treatment questions

That is why this subtype often needs its own home, even when some of the most useful material still overlaps with the ER-positive and HER2-positive sections.

What this subtype usually raises

Triple-positive disease often brings a mixed set of questions, such as:

• how ER and HER2 signalling interact

• when endocrine resistance matters

• how HER2-targeted therapy changes the picture

• how subtype labels like luminal B may overlap with treatment thinking

• where support threads sit when a question is partly endocrine and partly HER2-driven

Relevant support group threads and docs

Triple-positive-specific thread

• 💬 Triple Positive Breast Cancer (TPBC)

Current overlap pages are worth checking

Until this section grows further, the most relevant overlap pages currently live in the HER2-Positive and ER-Positive / HER2-Negative sections.

More HER2-linked material

• HER2-Positive

• Support Threads & Docs

• Should HER2+/ERα+ Patients Avoid Resveratrol or Polydatin?

• Enhertu and Cancer Cell Senescence

More ER-linked material

• ER-Positive / HER2-Negative

• ER+/PR- Receptor Status

• Distinguishing Luminal A from Luminal B

• Support Threads & Docs

How this section will grow

This section will expand to include:

• triple-positive-treatment-specific resistance questions

• endocrine-plus-HER2 treatment overlap notes

• support-thread links pulled across from both ER-positive and HER2-positive sections

• subtype-specific practical questions on sequencing, side effects, and adjunctive support